Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -0.10% | 159.87 | 0.0% | $1295.48m | |
| AMGN | Amgen, Inc. | 2.21% | 255.13 | 1.3% | $694.68m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | 1.90% | 8.03 | 0.7% | $561.33m | |
| NVAX | Novavax, Inc. | 0.37% | 202.09 | 80.0% | $556.50m | |
| ILMN | Illumina, Inc. | 0.98% | 401.96 | 3.5% | $517.94m | |
| GILD | Gilead Sciences, Inc. | 0.72% | 65.77 | 1.0% | $463.29m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.80% | 494.64 | 2.7% | $449.68m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 1.83% | 221.10 | 1.9% | $383.88m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.45% | 157.54 | 2.0% | $298.86m | |
| BNTX | BioNTech SE | 6.12% | 140.72 | 0.0% | $266.37m | |
| BIIB | Biogen, Inc. | 1.75% | 270.44 | 1.7% | $264.45m | |
| EXAS | EXACT Sciences Corp. | 2.66% | 130.52 | 18.4% | $192.20m | |
| NBIX | Neurocrine Biosciences, Inc. | -0.05% | 95.00 | 4.9% | $177.73m | |
| CRSP | CRISPR Therapeutics AG | 0.60% | 123.85 | 0.6% | $174.50m | |
| SGEN | Seagen Inc. | 3.77% | 149.64 | 5.8% | $153.69m |
Company Profile
Otonomy, Inc. operates as a biopharmaceutical company. It engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.